Appili Therapeutics Inc - Asset Resilience Ratio
Appili Therapeutics Inc (APLI) has an Asset Resilience Ratio of 0.00% as of March 2022. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Appili Therapeutics Inc balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2022)
This chart shows how Appili Therapeutics Inc's Asset Resilience Ratio has changed over time. See Appili Therapeutics Inc book value and equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Appili Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Appili Therapeutics Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$0.00 | 0% |
| Short-term Investments | CA$0.00 | 0% |
| Total Liquid Assets | CA$0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Appili Therapeutics Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Appili Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Appili Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Argen-X
F:1AE |
Biotechnology | 25.67% |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229 |
Biotechnology | 0.21% |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333 |
Biotechnology | 35.96% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.48% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 70.49% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
Annual Asset Resilience Ratio for Appili Therapeutics Inc (2017–2022)
The table below shows the annual Asset Resilience Ratio data for Appili Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-03-31 | 0.00% | CA$0.00 ≈ $0.00 |
CA$8.28 Million ≈ $5.99 Million |
-- |
| 2021-03-31 | 27.63% | CA$5.06 Million ≈ $3.66 Million |
CA$18.32 Million ≈ $13.25 Million |
+27.36pp |
| 2020-03-31 | 0.27% | CA$30.54K ≈ $22.09K |
CA$11.17 Million ≈ $8.08 Million |
-0.17pp |
| 2019-03-31 | 0.45% | CA$30.48K ≈ $22.05K |
CA$6.84 Million ≈ $4.94 Million |
+0.02pp |
| 2018-03-31 | 0.42% | CA$30.32K ≈ $21.93K |
CA$7.19 Million ≈ $5.20 Million |
-0.36pp |
| 2017-03-31 | 0.78% | CA$20.14K ≈ $14.57K |
CA$2.57 Million ≈ $1.86 Million |
-- |
About Appili Therapeutics Inc
Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a liquid oral taste-masked reformulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paro… Read more